Figure 1



Mean blood concentration of IMAB362 by infused dose
Concentration mean [µg/ml]
550
500
450
400
350
300
250
200
150
100
50
0
-2
0
3
8
12
24
48
96
168
336
672
Hours after end of infusion
Treatment dose
33mg/m2
100mg/m2
300mg/m2
600mg/m2
1000mg/m2

Figure 2






A
Max. specific killing (%)
100
80
60
40
20
0
p= 0.3362
Healthy donor PBMCs
Patient PBMCs
B
IMAB362:
0.32 µg/ml
3.16 µg/ml
31.63 µg/ml
Specific killing (%)
100
80
60
40
20
0
n.a.
Patient #
Days after infusion:
0203
0201
0202
0403
0204
0205
7
14

Figure 2


C
Specific killing (%)
100
80
60
40
20
0
1
2
3
4
5
log IMAB362 concentration [ng/ml]
control of 0403
control of 0202
control of 0201
control of 0203
control of 0204
control of 0205


D
Specific killing (%)
100
80
60
40
20
0
1
2
3
4
5
log IMAB362 concentration [ng/ml]
Patient 0204
Patient 0203
Patient 0403
Patient 0201
Patient 0205


E
Half maximum killing [ng/ml]
10^5
10^4
10^3
10^2
10^1
Healthy donor PBMCs
Patient PBMCs



Specific lysis (%)
100
80
60
40
20
0
10.0
3.2
1.0
0.5
0.3
10.0 (hi)
HSC
0.5
0.5
0.5
0.5
0.5
0.5
0201
0202
0203
0403
0204
0205
Patient
IMAB362 [µg/ml]

Figure 3

Figure 4



A
pre-infusion serum
after IMAB362 infusion:
1 day
7 days
14 days
28-32 days
Specific lysis (%)
100
80
60
40
20
0
10.0
3.2
1.0
0.5
0.3
10.0 (hi)
0.5
0.5
0.5
0.5
0.46
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
IMAB362 [µg/ml]
HSC
0201
0202
0203
Patient
33
100
Dose [mg/m 2]

Figure 4



B
Specific lysis (%)
100
80
60
40
20
0
10.0
3.2
1.0
0,5
0.3
10.0 (hi)
0.5
0.5
0.5
0.5
0.5
0.5
0.5
n.a.
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
IMAB362 [µg/ml]
HSC
0403
0204
0205
Patient
300
600
1000
Dose [mg/m2]

Figure 4

C



* p=0.0302
* p=0.0146
* p=0.0359
Specific lysis (%)
100
80
60
40
20
0
IMAB362:
fresh
24h
7d
14d
28-32d
after administration

Figure 5



Specific killing (%)
100
80
60
40
20
0
after IMAB362 infusion:
1 day
7 days
14 days
28-32 days
IMAB362 [µg/ml]
HSC
200.0
PSC
200.0
2.8
1.7
1.3
0.6
PSC
200.0
10.3
4.3
3.2
1.6
PSC
200.0
9.2
4.6
3.2
1.6
Patient
0201
0202
0203
Dose [mg/m²]
33
100
100

Figure 5



Specific killing (%)
100
80
60
40
20
0
HSC
PSC
0403
300
200.0
10.3
4.3
3.2
1.6
PSC
0204
600
200.0
85.1
n.a.
21.9
13.2
PSC
0205
1000
200.0
85.6
38.8
26.5
9.7
IMAB362 [µg/ml]
Patient
Dose [mg/m²]

Figure 6



Specific killing (%)
100
80
60
40
20
0
after IMAB362 infusion:
1 day
7 days
14 days
28-32 days
IMAB362 [µg/ml]
HSC 10.0
PSC 10.0
2.8
1.7
1.3
0.6
PSC 10.0
10.3
4.3
3.2
1.6
PSC 10.0
9.2
4.6
3.2
1.6
Patient
0201
0202
0203
Dose [mg/m²]
33
100
100

Figure 6




Specific killing (%)
100
80
60
40
20
0
HSC 10.0
PSC 10.0 10.3 4.3 3.2 1.6
PSC 10.0 85.1 n.a. 21.9 13.2
PSC 10.0 85.6 38.8 26.5 9.7
IMAB362 [µg/ml]
0403
300
0204
600
0205
1000
Patient
Dose [mg/m2]

Figure 7


after IMAB362 infusion:
1 day
7 days
14 days
28-32 days
Specific lysis (%)
100
80
60
40
20
0
10.0
3.2
1.0
0.3
10.0
2.2
1.3
1.1
0.5
10.0
8.3
3.4
2.6
1.3
10.0
7.3
3.6
2.5
1.3
IMAB362 [µg/ml]
PSC
PSC
PSC
HSC
0201
0202
0203
Patient
33
100
100
Dose [mg/m2]



Specific lysis (%)
100
80
60
40
20
0
IMAB362 [µg/ml]
Patient
Dose [mg/m²]
HSC
10.0
3.2
1.0
0.3
PSC
0403
300
10.0
22.8
8.7
4.2
2.3
PSC
0204
600
10.0
68.1
n.a.
17.5
10.6
PSC
0205
1000
10.0
68.8
31.1
21.2
7.8

Figure 7



IMAB362 [µg/mL]
1000
100
50
25
10
0.2
0.4
0.6
0.8
1.0
2
20
40
60
80
Time [days]
IMAB362 [µg/mL]
500
100
50
25
10
0.2
0.4
0.6
0.8
1.0
2
20
40
60
80
Time [days]

Figure 8




Kaplan-Meier Plot for PFS
FAS
clinical benefit
no clinical benefit
Survival [%]
100
80
60
40
20
0
0
10
20
30
40
50
[weeks]

Figure 9

Figure 10


Kaplan-Meier Plot for PFS
PP
clinical benefit
no clinical benefit
Survival [%]
100
80
60
40
20
0
0
10
20
30
40
50
[weeks]